Published in Drug Alcohol Depend on July 07, 2012
Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend (2014) 1.78
Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? Life Sci (2013) 1.28
Baths salts, spice, and related designer drugs: the science behind the headlines. J Neurosci (2014) 1.14
Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci (2013) 1.12
Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Neuropharmacology (2013) 1.06
Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol (2015) 0.94
Cross-substitution of Δ9-tetrahydrocannabinol and JWH-018 in drug discrimination in rats. Pharmacol Biochem Behav (2014) 0.92
Inhaled delivery of Δ(9)-tetrahydrocannabinol (THC) to rats by e-cigarette vapor technology. Neuropharmacology (2016) 0.90
In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ9-THC in mice: inhalation versus intraperitoneal injection. Pharmacol Biochem Behav (2014) 0.89
Emerging drugs of abuse: current perspectives on synthetic cannabinoids. Subst Abuse Rehabil (2015) 0.88
CB1 receptor-mediated signaling underlies the hippocampal synaptic, learning, and memory deficits following treatment with JWH-081, a new component of spice/K2 preparations. Hippocampus (2014) 0.87
Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential. Curr Addict Rep (2014) 0.83
Ethanol induced acetylation of histone at G9a exon1 and G9a-mediated histone H3 dimethylation leads to neurodegeneration in neonatal mice. Neuroscience (2013) 0.82
"Herbal incense": designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays. Life Sci (2013) 0.82
Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice. Neuropharmacology (2016) 0.77
Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies. Psychopharmacology (Berl) (2016) 0.75
Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice. Subst Abuse (2017) 0.75
Development of a high-performance liquid chromatography-tandem mass spectrometry method for the identification and quantification of CP-47,497, CP-47,497-C8 and JWH-250 in mouse brain. J Anal Toxicol (2014) 0.75
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol (2008) 5.32
Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch Arztebl Int (2009) 2.94
'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom (2009) 2.86
"Spice" girls: synthetic cannabinoid intoxication. J Emerg Med (2010) 2.76
Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav (1991) 2.57
The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res (2010) 2.45
Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett (2010) 2.24
Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci (2005) 2.13
Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther (1998) 1.97
The ring test: a quantitative method for assessing the 'cataleptic' effect of cannabis in mice. Br J Pharmacol (1972) 1.86
JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol (2010) 1.79
Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One (2011) 1.69
A teenager with agitation: higher than she should have climbed. Pediatr Emerg Care (2010) 1.61
Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila) (2011) 1.56
Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med (2011) 1.55
Adolescents' reported reasons for alcohol and marijuana use as predictors of substance use and problems in adulthood. J Stud Alcohol Drugs (2011) 1.43
Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J Mass Spectrom (2011) 1.42
Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther (2005) 1.39
Three cases of "spice" exposure. Clin Toxicol (Phila) (2011) 1.34
Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend (2011) 1.32
Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction (2010) 1.30
JWH-018 and JWH-073: Δ⁹-tetrahydrocannabinol-like discriminative stimulus effects in monkeys. J Pharmacol Exp Ther (2011) 1.28
Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats. Behav Pharmacol (2011) 1.27
1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice. Drug Alcohol Depend (2011) 1.18
Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice. J Pharmacol Exp Ther (2001) 1.09
Disposition of cannabichromene, cannabidiol, and Δ⁹-tetrahydrocannabinol and its metabolites in mouse brain following marijuana inhalation determined by high-performance liquid chromatography-tandem mass spectrometry. J Anal Toxicol (2010) 1.07
Liquid chromatography-tandem mass spectrometry analysis of urine specimens for K2 (JWH-018) metabolites. J Anal Toxicol (2011) 1.00
The pharmacological activity of inhalation exposure to marijuana smoke in mice. Drug Alcohol Depend (2001) 0.97
Panic attack after spice abuse in a patient with ADHD. Pharmacopsychiatry (2010) 0.96
SR 141716 (Rimonabant) precipitates withdrawal in marijuana-dependent mice. Pharmacol Biochem Behav (2006) 0.91
Synthetic cannabinoids in oral fluid. J Anal Toxicol (2011) 0.90
Anandamide, an endogenous cannabinoid, has a very low physical dependence potential. J Pharmacol Exp Ther (1998) 0.89
Detection of synthetic cannabinoids in herbal incense products. Clin Biochem (2011) 0.89
AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice. Psychopharmacology (Berl) (2011) 0.88
Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. Psychopharmacology (Berl) (2011) 0.84
Effects of delta-9-tetrahydrocannabinol on social behaviour in the laboratory mouse and rat. Psychopharmacologia (1975) 0.80
A pharmacological analysis of levonantradol antinociception in mice. J Clin Pharmacol (1982) 0.79
Detection and disposition of JWH-018 and JWH-073 in mice after exposure to "Magic Gold" smoke. Forensic Sci Int (2012) 0.79
Determination of naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in mouse blood and tissue after inhalation exposure to 'buzz' smoke by HPLC/MS/MS. Biomed Chromatogr (2012) 0.79
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol (2008) 5.32
Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science (2011) 3.48
Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci (2010) 3.11
Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A (2009) 2.68
Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol (2003) 2.45
Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci U S A (2004) 2.23
Evaluation of CB1 receptor knockout mice in the Morris water maze. J Pharmacol Exp Ther (2002) 1.60
Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) (2007) 1.53
Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J Neurosci (2003) 1.43
The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol (2004) 1.38
A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin Toxicol (Phila) (2013) 1.36
Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J (2009) 1.36
Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther (2008) 1.35
Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav (2010) 1.33
Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology (2006) 1.32
Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J (2009) 1.31
FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration. Neuropsychopharmacology (2010) 1.25
Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation. Learn Mem (2007) 1.24
The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem Phys Lipids (2002) 1.23
Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology (2010) 1.19
Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice. Biol Psychiatry (2012) 1.19
Hippocampal CB(1) receptors mediate the memory impairing effects of Delta(9)-tetrahydrocannabinol. Neuropsychopharmacology (2009) 1.19
Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. J Pharmacol Exp Ther (2010) 1.16
Lysosomal targeting and trafficking of acid sphingomyelinase to lipid raft platforms in coronary endothelial cells. Arterioscler Thromb Vasc Biol (2008) 1.16
High-performance liquid chromatography with tandem mass spectrometry for the determination of nine hallucinogenic 25-NBOMe designer drugs in urine specimens. J Anal Toxicol (2014) 1.16
Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms. J Pain (2010) 1.15
Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice. J Pharmacol Exp Ther (2011) 1.14
Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum. Neuron (2012) 1.13
Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet. J Pharmacol Exp Ther (2010) 1.12
Evaluation of fatty acid amides in the carrageenan-induced paw edema model. Neuropharmacology (2007) 1.11
Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. J Pharmacol Exp Ther (2013) 1.11
Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. J Pharmacol Exp Ther (2011) 1.07
Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett (2008) 1.07
Disposition of cannabichromene, cannabidiol, and Δ⁹-tetrahydrocannabinol and its metabolites in mouse brain following marijuana inhalation determined by high-performance liquid chromatography-tandem mass spectrometry. J Anal Toxicol (2010) 1.07
High-performance liquid chromatography tandem mass spectrometry method for the determination of 2CC-NBOMe and 25I-NBOMe in human serum. Biomed Chromatogr (2013) 1.05
The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. Life Sci (2012) 1.04
The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br J Pharmacol (2012) 1.01
Acid sphingomyelinase gene deficiency ameliorates the hyperhomocysteinemia-induced glomerular injury in mice. Am J Pathol (2011) 1.00
Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors. Eur J Pharmacol (2006) 1.00
The disruptive effects of the CB1 receptor antagonist rimonabant on extinction learning in mice are task-specific. Psychopharmacology (Berl) (2007) 1.00
Fatty acid amide hydrolase (-/-) mice exhibit an increased sensitivity to the disruptive effects of anandamide or oleamide in a working memory water maze task. J Pharmacol Exp Ther (2005) 1.00
The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. Neuropharmacology (2010) 0.99
Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice. J Pharmacol Exp Ther (2010) 0.99
Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. Pharmacol Biochem Behav (2011) 0.98
Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. Eur J Pharmacol (2010) 0.98
A rapid HPLC procedure for analysis of analgesic pharmaceutical mixtures for quality assurance and drug diversion testing. J Anal Toxicol (2005) 0.97
Combination of rimonabant and donepezil prolongs spatial memory duration. Neuropsychopharmacology (2007) 0.97
Endocannabinoid modulation of scratching response in an acute allergenic model: a new prospective neural therapeutic target for pruritus. J Pharmacol Exp Ther (2009) 0.96
Dual fatty acid amide hydrolase and monoacylglycerol lipase blockade produces THC-like Morris water maze deficits in mice. ACS Chem Neurosci (2012) 0.96
Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal (2013) 0.95
Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells. Biochim Biophys Acta (2010) 0.94
Effects of α7 positive allosteric modulators in murine inflammatory and chronic neuropathic pain models. Neuropharmacology (2012) 0.94
Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice. Neuropsychopharmacology (2013) 0.93
Triggering role of acid sphingomyelinase in endothelial lysosome-membrane fusion and dysfunction in coronary arteries. Am J Physiol Heart Circ Physiol (2010) 0.93
The cannabinoid CB2 receptor is necessary for nicotine-conditioned place preference, but not other behavioral effects of nicotine in mice. Psychopharmacology (Berl) (2013) 0.93
SR 141716 (Rimonabant) precipitates withdrawal in marijuana-dependent mice. Pharmacol Biochem Behav (2006) 0.91
Exposure to marijuana smoke impairs memory retrieval in mice. J Pharmacol Exp Ther (2007) 0.91
Novel bioactive metabolites of dipyrone (metamizol). Bioorg Med Chem (2011) 0.91
Formation of lipid raft redox signalling platforms in glomerular endothelial cells: an early event of homocysteine-induced glomerular injury. J Cell Mol Med (2009) 0.91
The role of fatty acid amide hydrolase inhibition in nicotine reward and dependence. Life Sci (2012) 0.89
"My friend said it was good LSD": a suicide attempt following analytically confirmed 25I-NBOMe ingestion. J Psychoactive Drugs (2014) 0.89
Differential endocannabinoid regulation of extinction in appetitive and aversive Barnes maze tasks. Learn Mem (2008) 0.89
Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol. Drug Alcohol Depend (2010) 0.89
NIH 11082 produces anti-depressant-like activity in the mouse tail-suspension test through a delta-opioid receptor mechanism of action. Eur J Pharmacol (2007) 0.88
Δ8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors. Br J Pharmacol (2012) 0.88
Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents. Psychopharmacology (Berl) (2010) 0.88
Perinatal nicotine exposure eliminates peak in nicotinic acetylcholine receptor response in adolescent rats. J Pharmacol Exp Ther (2006) 0.88
Differential behavioral responses to nicotine in Lewis and Fischer-344 rats. Pharmacol Biochem Behav (2004) 0.87
Reversible competitive α-ketoheterocycle inhibitors of fatty acid amide hydrolase containing additional conformational constraints in the acyl side chain: orally active, long-acting analgesics. J Med Chem (2011) 0.87
Analysis of the first- and second-generation Raving Dragon Novelty Bath Salts containing methylone and pentedrone. J Forensic Sci (2014) 0.86
Drinking water exposure to cadmium, an environmental contaminant, results in the exacerbation of autoimmune disease in the murine model. Toxicology (2003) 0.86
Dissimilar cannabinoid substitution patterns in mice trained to discriminate Δ(9)-tetrahydrocannabinol or methanandamide from vehicle. Behav Pharmacol (2011) 0.86
In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. Behav Pharmacol (2014) 0.86
Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide. J Enzyme Inhib Med Chem (2012) 0.85
Evolution of the NBOMes: 25C- and 25B- Sold as 25I-NBOMe. J Med Toxicol (2015) 0.85
Large-scale neurochemical metabolomics analysis identifies multiple compounds associated with methamphetamine exposure. Metabolomics (2012) 0.85
The endogenous cannabinoid anandamide shares discriminative stimulus effects with ∆(9)-tetrahydrocannabinol in fatty acid amide hydrolase knockout mice. Eur J Pharmacol (2011) 0.85
Production and actions of the anandamide metabolite prostamide E2 in the renal medulla. J Pharmacol Exp Ther (2012) 0.85
Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. Drug Alcohol Depend (2009) 0.85
Rational design of fatty acid amide hydrolase inhibitors that act by covalently bonding to two active site residues. J Am Chem Soc (2013) 0.84
An evaluation of the OnTrak Testcup-er on-site urine drug-testing device for drugs commonly encountered from emergency departments. J Anal Toxicol (2002) 0.83
Cannabinoid exposure during zebra finch sensorimotor vocal learning persistently alters expression of endocannabinoid signaling elements and acute agonist responsiveness. BMC Neurosci (2011) 0.83
Evaluation of the DRI oxycodone immunoassay for the detection of oxycodone in urine. J Anal Toxicol (2005) 0.82
Cellular nicotinic receptor desensitization correlates with nicotine-induced acute behavioral tolerance in rats. Psychopharmacology (Berl) (2007) 0.82
The effects of acute and repeated nicotine doses on spontaneous activity in male and female Sprague Dawley rats: analysis of brain area epibatidine binding and cotinine levels. Pharmacol Biochem Behav (2008) 0.82
CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action. Psychopharmacology (Berl) (2011) 0.81
Fatty acid amide hydrolase (FAAH) knockout mice exhibit enhanced acquisition of an aversive, but not of an appetitive, Barnes maze task. Neurobiol Learn Mem (2009) 0.81